Principal Financial Group Inc. cut its stake in Horizon Therapeutics Public Limited (NASDAQ:HZNP – Free Report) by 95.1% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 41,534 shares of the biopharmaceutical company’s stock after selling 800,406 shares during the quarter. Principal Financial Group Inc.’s holdings in Horizon Therapeutics Public were worth $4,533,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Vanguard Group Inc. increased its stake in shares of Horizon Therapeutics Public by 0.9% in the 1st quarter. Vanguard Group Inc. now owns 20,328,877 shares of the biopharmaceutical company’s stock worth $2,138,801,000 after acquiring an additional 190,183 shares during the last quarter. Avoro Capital Advisors LLC increased its position in shares of Horizon Therapeutics Public by 36.6% during the 4th quarter. Avoro Capital Advisors LLC now owns 7,000,000 shares of the biopharmaceutical company’s stock worth $796,600,000 after purchasing an additional 1,875,000 shares during the last quarter. State Street Corp increased its position in shares of Horizon Therapeutics Public by 3.4% during the 3rd quarter. State Street Corp now owns 5,732,387 shares of the biopharmaceutical company’s stock worth $354,777,000 after purchasing an additional 188,413 shares during the last quarter. T. Rowe Price Investment Management Inc. acquired a new stake in shares of Horizon Therapeutics Public during the 4th quarter worth about $460,920,000. Finally, Geode Capital Management LLC increased its position in shares of Horizon Therapeutics Public by 1.8% during the 4th quarter. Geode Capital Management LLC now owns 3,073,801 shares of the biopharmaceutical company’s stock worth $349,392,000 after purchasing an additional 54,463 shares during the last quarter. 80.37% of the stock is owned by institutional investors and hedge funds.
Horizon Therapeutics Public Stock Performance
NASDAQ HZNP opened at $115.30 on Friday. The stock has a 50-day moving average of $103.85 and a two-hundred day moving average of $105.93. The company has a debt-to-equity ratio of 0.48, a current ratio of 4.27 and a quick ratio of 4.09. The company has a market cap of $26.40 billion, a P/E ratio of 61.66, a P/E/G ratio of 3.41 and a beta of 1.05. Horizon Therapeutics Public Limited has a 1-year low of $59.16 and a 1-year high of $115.70.
Analyst Ratings Changes
HZNP has been the subject of a number of recent analyst reports. Jefferies Financial Group downgraded Horizon Therapeutics Public from a “buy” rating to a “hold” rating in a research report on Friday. TheStreet downgraded Horizon Therapeutics Public from a “b-” rating to a “c+” rating in a research report on Monday, May 8th. Finally, StockNews.com raised Horizon Therapeutics Public from a “buy” rating to a “strong-buy” rating in a research report on Monday, August 28th. Eight investment analysts have rated the stock with a hold rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Horizon Therapeutics Public has an average rating of “Hold” and an average target price of $110.71.
Horizon Therapeutics Public Company Profile
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation.
- Five stocks we like better than Horizon Therapeutics Public
- Investing In Preferred Stock vs. Common Stock
- MarketBeat Week in Review – 8/28 – 9/1
- What to Know About Investing in Penny Stocks
- 2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
- How to Invest in the FAANG Stocks
- Toyota vs Tesla: The Tortoise And The Hare Race Has A New Meaning
Receive News & Ratings for Horizon Therapeutics Public Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Public and related companies with MarketBeat.com's FREE daily email newsletter.